Cintas Corporation Climbs Ten Spots on the Fortune 500 List
CINCINNATI--(BUSINESS WIRE)-- Cintas Corporation (Nasdaq: CTAS) has maintained its status as a Fortune 500 company for the eighth consecutive year, coming in at 427. Cintas has improved its position in the Fortune 500 rankings, rising ten spots.
To qualify for the Fortune 500 list, the magazine considers U.S.-based companies that submit financial statements to a government agency. Companies are then ranked based on their total revenues for their respective fiscal years as of January 31, 2025.
Cintas' most recent fully disclosed fiscal year, FY24, ended on May 31, 2024. During that year, the company recorded revenues of $9.60 billion, an 8.9% increase from its fiscal year 2023 performance of $8.82 billion.
'Sustaining this honor for eight consecutive years speaks volumes to the dedication of our more than 46,000 employee-partners and the exceptional service they provide to our customers,' said Todd Schneider, President and CEO of Cintas. 'We take pride in the trust our customers place in us, allowing their businesses to remain ready for the workday. It's an honor for us to be recognized amongst some of the best and most successful companies in the country.'
Cintas concluded its fiscal year, FY25, on May 31, 2025, and will report on the full-year results in July 2025. In the first three quarters of disclosed FY'25 earnings, Cintas reported revenues of $7.67 billion. This amount exceeded the equivalent FY'24 revenues of $7.13 billion by 7.57%.
About Cintas Corporation
Cintas Corporation helps more than one million businesses of all types and sizes get Ready™ to open their doors with confidence every day by providing products and services that help keep their customers' facilities and employees clean, safe, and looking their best. With offerings including uniforms, mats, mops, towels, restroom supplies, workplace water services, first aid and safety products, eye-wash stations, safety training, fire extinguishers, sprinkler systems and alarm service, Cintas helps customers get Ready for the Workday®. Headquartered in Cincinnati, Cintas is a publicly held Fortune 500 company traded over the Nasdaq Global Select Market under the symbol CTAS and is a component of both the Standard & Poor's 500 Index and Nasdaq-100 Index.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
A 21-year-old asked his grandmother for money to open a street-food stall. Now, it's the world's largest fast-food chain, eclipsing McDonald's
It may surprise you to learn that the world's largest fast-food chain isn't an American staple like McDonald's or Starbucks. It's actually Mixue, an ice cream and boba shop founded in 1997 that has exploded in popularity in China and throughout Asia. Zhang Hongchao was a university student when he created the first Mixue stall; now he's a billionaire. McDonald's was founded 85 years ago in San Bernardino, Calif. It's the world's second-largest private employer—behind only Walmart, No. 1 on the Fortune 500 again this year—and has over 40,000 locations worldwide. Yet, McDonald's still falls behind one company in terms of footprint: Mixue Ice Cream & Tea. Mixue, as of March, is currently the world's largest fast-food chain by store locations, with over 46,000 sites across Asia, Australia, the Middle East, and South America. Roughly 40,000 of its total locations exist in mainland China, meaning the company has even more room to run globally. And the company's performed well since its March debut on Hong Kong's stock exchange, soaring from its opening price of $290 HKD per share to $584.50 HKD as of Monday morning. Zhang Hongchao probably didn't expect to be the founder of such a behemoth when he opened his first street-food stall 28 years ago. Zhang was attending the Henan University of Economics and Law when he had the idea to open a food stall, mainly to sell beverages like cold drinks and shaved ice. He asked his grandmother to borrow 3,000 yuan—around $362 back then, or $417 today—to open up a small stall on the streets of Zhengzhou, the capital of China's Henan province and a major international transport hub. The stall was successful, even early on. According to a lengthy profile about Mixue in China's state-run outlet Sina News, Zhang was able to sell products worth up to 1.5 yuan for more than 100 yuan; in other words, he could make a drink that cost around 21 cents and sell it for more than $14. Unfortunately, Zhang's inexperience, and the rapid modernization of Zhengzhou, would become obstacles. The villages of Zhengzhou were constantly subject to demolition efforts as the area grew more urban, which resulted in Zhang's store getting demolished three times in a single year, according to Sina News. And he learned the hard way how difficult it is to sell cold treats during the winter season, which forced him to sell mandarin oranges for extra cash. Despite the setbacks, Zhang kept at it. He bought more machines, added more sugary drinks to his menu, and notably introduced a soft-serve ice cream cone for just 1 yuan, or roughly 14 cents, which solidified the brand among budget-conscious consumers. The company also got stronger operational chops when Zhang brought in his younger brother, Hongfu, to help run the company in 2007. Since so many of Mixue's franchisees were run by friends or family, few enforced Zhang's rules or regulations; that changed when Hongfu, who now acts as the company's CEO, took the reins. (Elder brother Hongchao Zhang, the founder, serves as chairman.) One of the most important things Hongfu did was introduce store managers, which ultimately helped the two brothers avoid disputes with family members who operated some of their franchises. As Mixue added hundreds of stores over the years, the company grappled with quality and consistency issues, as well as supply-chain woes when fruits or milk powder ran in short supply. But sales rebounded as Zhang pushed for new products like boba tea, and supply issues were ameliorated when Zhang decided to establish a storage base in 2014 that would collect raw materials from farmers, and produce its own materials like powders and snacks, essentially consolidating a large portion of its supply chain. In 2022, Mixue reported having warehouse and logistics bases in 22 different provinces, and the company has stepped up quality-control efforts to avoid store closures. Mixue controls site selection, store decoration, personnel training, raw material supply, and food safety to ensure the success of its franchisees. In 2024, Mixue reported 4.4 billion yuan ($615 million) in profit, up 22% over the year before, on 24.8 billion yuan (about $3.43 billion) in revenue, which was a near-40% jump year over year. Its earnings per share, 12.3 yuan ($1.71), was also up 41% from 2023. The company's vertically integrated supply chain and proprietary logistics network have helped keep costs low at just 30% of its sales revenue, compared to the industry average of 45%–55%, according to a recent study published in the Journal of Fintech and Business Analysis. Crucially, the company continues to expand. It added 4,192 new franchisees in 2024 and opened over 10,000 new stores, with a closure rate of just 3.5%. While over 99% of its 45,000-plus stores are franchised, franchise fees only make up a small percentage of its revenue. According to the company, the bulk of its income comes from selling merchandise and equipment to franchises, which are required to buy these items directly from Mixue. Earlier this year, Mixue celebrated a successful initial public offering, one of the biggest IPOs of Hong Kong's Stock Exchange this year so far, raising $3.45 billion HKD, or $444 million. As for the Zhang brothers, Hongchao and Hongfu maintain relatively low profiles, but reportedly have a combined net worth of $8.1 billion. This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ('Merus', the 'Company,' 'we' and 'our'), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the 'Offer Shares'). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the 'Option Shares' and together with the Offer Shares, the 'Shares'). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus. The offering is expected to close on or about June 5, 2025, subject to customary closing conditions. Merus currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes. Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital are acting as joint book-running managers for the offering. Van Lanschot Kempen is acting as lead manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission ('SEC') on February 28, 2024 and was effective upon filing. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, which, for the avoidance of doubt, will not constitute a 'prospectus' for the purposes of (i) Regulation (EU) 2017/1129 (the 'Prospectus Regulation') and has not been reviewed by any competent authority in any member state in the European Economic Area (the 'EEA') and (ii) the Prospectus Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the 'UK Prospectus Regulation') and has not been reviewed by the Financial Conduct Authority in the United Kingdom. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on June 3, 2025, and a final prospectus supplement will be filed with the SEC and will be available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ BofA Securities NC1-0220-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255‐0001, or by email at Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@ Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ or Truist Securities, Inc., Attention: Equity Capital Markets, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326 at (800) 685-4786 or by email to This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is an advertisement and not a prospectus within the meaning of either the Prospectus Regulation or the UK Prospectus Regulation. EEA: In relation to each member state of the EEA (each, a 'Relevant State'), no Shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that Shares may be offered to the public in that Relevant State at any time: to any legal entity which is a 'qualified investor' as defined under Article 2 of the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; and in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of the Shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. Each person who initially acquires any Shares or to whom any offer is made will be deemed to have represented, warranted, acknowledged and agreed to and with us and each of the underwriters that it is a 'qualified investor' within the meaning of Article 2 of the Prospectus Regulation. For the purposes of the above, the expression 'offer to the public' in relation to the Shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, and the expression 'Prospectus Regulation' means Regulation (EU) 2017/1129. United Kingdom: No Shares have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the Shares which has been approved by the Financial Conduct Authority in the United Kingdom, except that the Shares may be offered to the public in the United Kingdom at any time: a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or c) in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000 (the 'FSMA'), provided that no such offer of the Shares shall require us or any of the underwriters to publish a prospectus pursuant to Section 85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. Each person in the United Kingdom who initially acquires any Shares or to whom any offer is made will be deemed to have represented, warranted, acknowledged and agreed to and with us and each of the underwriters that it is a 'qualified investor' within the meaning of the UK Prospectus Regulation. For the purposes of this provision, the expression an 'offer to the public' in relation to the Shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares. In addition, in the United Kingdom, the transaction to which this press release relates will only be available to, and will be engaged in only with persons who are 'qualified investors' (as defined in the UK Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, as amended (the Order), and/or (ii) who are high net worth entities (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, the securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person in the United Kingdom who is not a relevant person should not act or rely on this communication or any of its contents. About Merus N.V. Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the completion of the proposed offering, the anticipated gross proceeds from the offering and our intended use of any net proceeds from the offering. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics®, Triclonics® and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the global instability caused by the Russia Ukraine conflict and conflict in the Middle East; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission, or SEC, on May 7, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics®, ADClonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V. CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 Kathleen Farren Merus N.V. Director Investor Relations and Corporate Communications 617-230-4165
Yahoo
an hour ago
- Yahoo
Broadcom Just Dropped a Chip That Could Supercharge 100,000 GPUs
Broadcom (NASDAQ:AVGO) is making a bold move to grab a bigger slice of the red-hot AI infrastructure pie. Over the weekend, the company began shipping its Tomahawk 6 chipits most powerful data center switch to date. Why does this matter? Because when you're running a supercomputer with 100,000+ GPUs, speed isn't just about the chipsit's about how fast they talk to each other. And that's exactly what Tomahawk 6 is built for. Ram Velaga, Broadcom's SVP of Core Switching, says the new chip can do the work of six old ones. That could mean faster AI training, better inference, and lower infrastructure bloat for the same GPU count. The underlying problem? Most GPUseven the powerful ones from Nvidia (NASDAQ:NVDA)are sitting idle 60% to 70% of the time, waiting for the network to catch up. Think of it like race cars stuck in traffic. Broadcom's switch could unclog those lanes. Early customers, including top cloud providers and networking firms, are already deploying the new chip to stitch together some of the world's largest GPU clusters. No names were dropped, but Velaga hinted at rollouts involving over 100,000 GPUs. Given that you typically need one switch for every 10 GPUs, the upside here could be huge. And while Tomahawk 6 won't come cheapcosting nearly double its predecessorBroadcom believes the performance payoff justifies the premium. Velaga didn't give an exact price but noted it's below $20,000 per unit, with bulk discounts likely in play. Full availability is coming in July. With AI data centers racing to optimize every watt, every connection, and every dollar, Broadcom might've just positioned itself as an indispensable piece of the next-generation AI stack. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
